GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Cash Conversion Cycle

BioDelivery Sciences International (FRA:BD5) Cash Conversion Cycle : 323.51 (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BioDelivery Sciences International's Days Sales Outstanding for the three months ended in Dec. 2021 was 118.58.
BioDelivery Sciences International's Days Inventory for the three months ended in Dec. 2021 was 303.21.
BioDelivery Sciences International's Days Payable for the three months ended in Dec. 2021 was 98.28.
Therefore, BioDelivery Sciences International's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2021 was 323.51.


BioDelivery Sciences International Cash Conversion Cycle Historical Data

The historical data trend for BioDelivery Sciences International's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Cash Conversion Cycle Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -84.97 30.21 100.53 200.41 328.95

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.34 298.97 393.09 338.34 323.51

Competitive Comparison of BioDelivery Sciences International's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Cash Conversion Cycle falls into.



BioDelivery Sciences International Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BioDelivery Sciences International's Cash Conversion Cycle for the fiscal year that ended in Dec. 2021 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=111.22+311.64-93.91
=328.95

BioDelivery Sciences International's Cash Conversion Cycle for the quarter that ended in Dec. 2021 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=118.58+303.21-98.28
=323.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioDelivery Sciences International  (FRA:BD5) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BioDelivery Sciences International Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines